PMID: 9416467Jan 7, 1998Paper

Protective effect of ACE inhibitors on ischemia-reperfusion-induced arrhythmias in rats: is this effect related to the free radical scavenging action of these drugs?

Free Radical Research
M BirinciogluA Acet

Abstract

The antiarrhythmic effects of captopril, a sulphydryl-containing angiotensin converting enzyme (ACE) inhibitor, were compared with those of the nonsulphydryl-containing ACE inhibitor lisinopril and the sulphydryl-containing agent glutathione in an in vivo rat model of coronary artery ligation. To produce arrhythmia, the left main coronary artery was occluded for 7 min, followed by 7 min of reperfusion. Captopril (3 mg kg-1) and lisinopril (0.1, 0.3 or 1 mg kg-1) caused marked decreases in mean arterial blood pressure (BP) and heart rate, whereas glutathione (5 mg kg-1) had no effect on them. The incidence of ventricular tachycardia (VT) on ischemia and reperfusion was significantly reduced by captopril and lisinopril. Captopril and 1 mg kg-1 lisinopril also significantly decreased the number of VEB during occlusion and the duration of VT on reperfusion, respectively. These drugs also attenuated the incidence of reversible ventricular fibrillation (VF) and the number of ventricular ectopic beats (VEB) during reperfusion. However, glutathione only reduced the incidence of VT on reperfusion, significantly. These results suggest that, in this experimental model, ACE inhibitors limit the arrhythmias following ischemia-reperfusion an...Continue Reading

References

Jan 1, 1992·Journal of Cardiovascular Pharmacology·W Linz, B A Schölkens
Jan 1, 1991·European Journal of Applied Physiology and Occupational Physiology·P L GreenhaffM Dunnett
Sep 30, 1991·The American Journal of Medicine·R FerrariO Visioli
Aug 1, 1990·Cardiovascular Drugs and Therapy·D J Hearse
Jul 18, 1989·European Journal of Pharmacology·L Carlsson, T Abrahamsson
Jun 1, 1984·Journal of Molecular and Cellular Cardiology·A S Manning, D J Hearse
Jun 1, 1993·Journal of Cardiovascular Pharmacology·J C HartmanR J Shebuski
Jan 1, 1996·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·A B Iskit, M O Guc

❮ Previous
Next ❯

Citations

May 24, 2005·Regulatory Peptides·Nermina JahovicInci Alican
Aug 26, 2000·Clinica Chimica Acta; International Journal of Clinical Chemistry·V B PatelV R Preedy
Jul 20, 2000·Clinica Chimica Acta; International Journal of Clinical Chemistry·D MantleV R Preedy
Feb 28, 2002·British Journal of Pharmacology·G F Baxter, Z Ebrahim
Sep 16, 2003·Critical Care Medicine·Manuel Ruiz-BailénUNKNOWN ARIAM Group
Sep 9, 2005·Cell Biochemistry and Function·Zeliha Selamoglu Talas, Muhittin Yurekli
May 16, 2006·Experimental Eye Research·Iliyana IlievaShigeaki Ohno
Apr 3, 2007·Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS·Hakan AydoganAhmet Acet
Jan 15, 2016·PloS One·Mortimer GierthmuehlenDennis T T Plachta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.